Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Shutter Connecticut Facility That Builds BeadXpress, Will Consolidate in San Diego

NEW YORK (GenomeWeb News) — Illumina plans to shutter its manufacturing operations in Wallingford, Conn., and fold some of the assets from the space into its San Diego facilities, the company said today.
 
The Wallingford site was originally established in connection with the acquisition of CyVera, and has helped Illumina develop and manufacture the BeadXpress system. The platform debuted last month.
 
Illumina CEO Jay Flatley said that the company decided to consolidate the facility after its recent acquisition of Solexa enabled the company to evaluate “all of our operations.” He said that combining the operations “will provide us with efficiencies from both the manufacturing and development perspective.”
  
It was not immediately clear whether the step would result in lay-offs.
 
Flatley said Illumina will concentrate its R&D and manufacturing work in San Diego and in its facility in Little Chesterford, UK.
 
The company said it will incur roughly $2 million in incremental charges related to the consolidation, and expects that the move will be complete “over the course of 2007."

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.